Probable Molecular Targeting of Inhibitory Effect of Carvacrol-Loaded Bovine Serum Albumin Nanoparticles on Human Breast Adenocarcinoma Cells.
10.1007/s11655-024-4122-9
- Author:
Pouria KHODAVANDI
1
;
Neda KARAMI
2
;
Alireza KHODAVANDI
3
;
Fahimeh ALIZADEH
4
;
Esmaeel Panahi KOKHDAN
5
;
Ahmad ZAHERI
6
Author Information
1. Department of Animal Science, Shiraz University, Shiraz, Iran.
2. Department of Biology, Gachsaran Branch, Islamic Azad University, Gachsaran, Iran.
3. Department of Biology, Gachsaran Branch, Islamic Azad University, Gachsaran, Iran. alireza_khodavandi@yahoo.com.
4. Department of Biology, Gachsaran Branch, Islamic Azad University, Gachsaran, Iran. mnalizadeh@yahoo.com.
5. Medicinal Plants Research Center, Yasuj University of Medical Sciences, Yasuj, Iran.
6. Department of Biology, Payame Noor University, Tehran, Iran.
- Publication Type:Journal Article
- Keywords:
MCF-7 cell;
breast cancer;
carvacrol;
gene expression;
nanocarrier;
nanoparticles
- MeSH:
Humans;
Cymenes;
Nanoparticles/ultrastructure*;
MCF-7 Cells;
Breast Neoplasms/genetics*;
Apoptosis/drug effects*;
Serum Albumin, Bovine/chemistry*;
Monoterpenes/therapeutic use*;
Adenocarcinoma/genetics*;
Cell Proliferation/drug effects*;
Reactive Oxygen Species/metabolism*;
Female;
Cell Survival/drug effects*;
Animals;
Gene Expression Regulation, Neoplastic/drug effects*;
Nitric Oxide/metabolism*;
Cattle
- From:
Chinese journal of integrative medicine
2025;31(4):336-346
- CountryChina
- Language:English
-
Abstract:
OBJECTIVE:To entrap carvacrol (CAR) in bovine serum albumin nanoparticles (BSANPs) to form CAR-loaded BSANPs (CAR@BSANPs) and to explore the anti-cancer effects in breast adenocarcinoma cells (MCF-7 cells) treated with CAR and CAR@BSANPs.
METHODS:A desolvation method was used to synthesize BSANPs and CAR@BSANPs. The BSANPs and CAR@BSANPs were characterized by several physicochemical methods, including visual observation, high-resolution field emission scanning electron microscopy, Fourier transform infrared spectroscopy, and high-performance liquid chromatography. MCF-7 cells were used and analyzed after 24 h of exposure to CAR and CAR@BSANPs at half-maximal inhibitory concentration. The anti-proliferative, apoptotic, reactive oxygen species (ROS), and nitric oxide (NO) scavenging activity as well as gene expression analysis were investigated by the cell viability assay, phase-contrast microscopy, 2',7'-dichlorofluorescein-diacetate assay, Griess-Illosvoy colorimetric assay, and quantitative real-time polymerase chain reaction, respectively.
RESULTS:CAR and CAR@BSANPs showed anti-proliferative, apoptotic, ROS generation, and NO scavenging effects on MCF-7 cells. Expression profile of B-cell lymphoma 2-like 11 (BCL2L11), vascular endothelial growth factor A (VEGFA), hypoxia inducible factor factor-1α (HIF1A), BCL2L11/apoptosis regulator (BAX), and BCL2L11/Bcl2 homologous antagonist/killer 1 (BAK1) ratios revealed downregulated genes; and BAX, BAK1, and CASP8 were upregulated by CAR and CAR@BSANPs treatment. In vitro anticancer assays of the CAR and CAR@BSANPs showed that CAR@BSANPs demonstrated higher therapeutic efficacy in the MCF-7 cells than CAR.
CONCLUSIONS:CAR and CAR@BSANPs affect gene expression and may subsequently reduce the growth and proliferation of the MCF-7 cells. Molecular targeting of regulatory genes of the MCF-7 cells with CAR and CAR@BSANPs may be an effective therapeutic strategy against breast cancer.
